PT  - JOURNAL ARTICLE
AU  - Yuan Bai
AU  - Zhanwei Du
AU  - Mingda Xu
AU  - Lin Wang
AU  - Peng Wu
AU  - Eric H. Y. Lau
AU  - Benjamin J. Cowling
AU  - Lauren Ancel Meyers
TI  - International risk of SARS-CoV-2 Omicron variant importations originating in South Africa
AID  - 10.1101/2021.12.07.21267410
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.07.21267410
4099  - http://medrxiv.org/content/early/2021/12/07/2021.12.07.21267410.short
4100  - http://medrxiv.org/content/early/2021/12/07/2021.12.07.21267410.full
AB  - Omicron, a fast-spreading SARS-CoV-2 variant of concern reported to the World Health Organization on November 24, 2021, has raised international alarm. We estimated there is at least 50% chance that Omicron had been introduced by travelers from South Africa into all of the 30 countries studied by November 27, 2021.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Collaborative Research Fund (Project No. C7123-20G) of the Research Grants Council of the Hong Kong SAR Government, the US National Institutes of Health (grant no. R01 AI151176), and the Centers for Disease Control and Prevention COVID Supplement (grant no. U01IP001136).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors